A number of presentations at the conference focused on
hepatitis C treatment for people who inject drugs, with an emphasis on new
interferon-free direct-acting antiviral therapies. (Treatment studies from the
meeting will be described in more detail in a forthcoming report.)
Jordan Feld of the University
of Toronto gave an overview of the current state of treatment, concluding that
while current therapies produce high cure rates – generally 90% or better – we
do not yet have a 'perfectovir'. Research is still needed on how well the new
treatments work for people who are current active drug injectors, as most PWID
studies have looked at those on OST. Simpler treatment regimens could help
increase the pool of hepatitis C treaters beyond hepatologists and infectious
disease specialists.
Expanded hepatitis C treatment is expected to prevent
liver disease progression among people who inject drugs. Over years or decades chronic HCV
infection can lead to advanced disease including liver cirrhosis,
decompensation (when the liver can no longer perform its vital functions),
hepatocellular carcinoma (HCC) and end-stage liver disease requiring a transplant.
Reem Waziry of the UNSW Kirby Institute presented
findings from a study of trends in end-stage liver disease among injection drug
users with HCV who either were or were not receiving OST. Rates of
decompensated cirrhosis and HCC rose overall between 2001 and 2013, but people
who had never received OST had both a higher rate and a steeper rise in both
conditions compared to those who had ever been on OST.
In addition to benefitting the health of people with
hepatitis C, effective treatment also means that cured patients will not
transmit HCV – a concept dubbed 'treatment as prevention'. Modelling studies
indicate that widespread treatment of populations including prisoners and drug
injectors could dramatically reduce HCV incidence.
But Magdalena Harris of the London School of Hygiene
and Tropical Medicine cautioned against over-emphasising
the prevention benefits of HCV treatment, stressing that people who inject drugs can find it alienating
as they do not want to be viewed as disease transmitters and are
concerned about the prospect of coerced treatment. "Treatment as prevention will
fail without prevention as prevention," Harris said.
Jude Byrne of the Australian
Injecting and Illicit Drug Users League, Carla Treloar of UNSW and others
discussed some of the barriers to hepatitis C diagnosis,
care and treatment – among them stigma and discrimination against people who
use drugs. Too often researchers "ignore the intelligence and agency of
PWID," Byrne said.
"People may be
unable or unwilling to jump through hoops to prove they deserve
treatment," Treloar added. "We need to provide care where people are,
not where we want them to be."
Finally, as with all recent meetings addressing
hepatitis C, the cost and cost-effectiveness of new HCV therapies was a major
topic. To date, high drug prices have led many government payers and private
insurers to restrict treatment to the sickest patients – and in some cases to
exclude people who have recently used drugs or alcohol.
Treatment that averts long-term consequences such as
liver cancer and transplantation may be cost-effective in the long run, but the
immediate cost of treating everyone with HCV is more than most payers can bear.
Yet treating hepatitis C in people who inject drugs is
the most cost effective way to address the sharp increase in liver disease and
death resulting from hepatitis C infection, according to experts.
"Without greatly enhanced treatment access, high
level hepatitis C transmission will continue, and the rising burden of liver
disease will lead to substantial costs to healthcare systems," Jason
Grebely of the Kirby Institute said in a UNSW press release. "Treatment of people who use drugs with hepatitis C saves lives
and is cost-effective. We need to step up treatment access for this group as a
major public health priority…Treating hepatitis C in people who use drugs will
not only reduce the future potential disease burden and reduce costs to our
healthcare system. It is also an important first step towards elimination of
HCV."
"Deaths and advanced liver disease associated
with long term hepatitis C infection are dramatically increasing in Australia.
We have not just effective but highly cost-effective therapies available to
redress this situation," added Annie Madden of the Australian Injecting
and Illicit Drug Users League. "At the end of the day, however, it is the
negative impact of stigma, discrimination, and criminalization that is
preventing people who need it most from accessing any kind of care in relation
to their hepatitis C. This needs to change and it needs to change now."